CHICAGO – An experimental drug dramatically slowed the expansion of glioma, a kind of mind most cancers, if the tumor carried a particular sort of genetic alteration, researchers stated Sunday, doubtlessly sparing sufferers publicity to radiation and chemotherapy.
The drug, vorasidenib, is made by Servier Prescribed drugs, a privately held drugmaker primarily based in France. The outcomes had been offered on the annual assembly of the American Society for Medical Oncology and printed within the New England Journal of Drugs.
Vorasidenib decreased the expansion of grade 2 glioma tumors by 61%, which means that it slowed the time it took tumors to be labeled as progressing, or develop by greater than a 3rd. Development took 11.1 months for many who took a placebo, and elevated to 27.7 months for many who took vorasidenib.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED